ArticleJournal of nanobiotechnology2025
Biomimetic cell membrane decorated calcium carbonate nanoparticles with asparaginase-metformin preloading for leukemia therapy.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Chemotherapy is the primary clinical treatment for leukemia, while its effectiveness is often limited due to undesired off-target effects and the reduced sensitivity of leukemia cells to chemotherapeutic agents. Therapies capable of targeting the bone marrow and addressing the acidic tumor microenvironment are anticipated to improve treatment efficacy. Here, we presented biomimetic cell membrane-decorated calcium carbonate nanoparticles co-loaded with asparaginase and metformin (AMNPs@CM) for bone marrow-targeted therapy of leukemia. The biomimetic cell membrane coating facilitated significant accumulation of AMNPs@CM in the bone marrow, where the nanoparticles released the payloads in response to the acidic tumor microenvironment. The released asparaginase and metformin could synergically induce mitochondrial dysfunction in leukemia cells, leading to inhibited cell proliferation and enhanced apoptosis. Thus, our stratagem could effectively inhibit tumor burden and prolong survival in a C1498 leukemia-bearing mouse model. These results indicate the potential of the AMNPs@CM as a bone marrow-targeted delivery platform for combination therapy in the treatment of leukemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.